{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:27:18Z","timestamp":1792045638048,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":322,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["R01CA181654"],"award-info":[{"award-number":["R01CA181654"]}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/s0021-9258(17)49933-9","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T20:50:07Z","timestamp":1609793407000},"page":"757-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers"],"prefix":"10.1016","volume":"295","author":[{"given":"Caroline C.","family":"Farrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeh","family":"Izadmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7436-9412","authenticated-orcid":false,"given":"Brittany L.","family":"Allen-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Janghorban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Wolczanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Sangodkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-4203","authenticated-orcid":false,"given":"Goutham","family":"Narla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0021-9258(17)49933-9_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/S0021-9258(17)49933-9_bib2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41598-017-00219-3","article-title":"Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors","volume":"7","author":"Ohshima","year":"2017","journal-title":"Sci. Rep"},{"key":"10.1016\/S0021-9258(17)49933-9_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","article-title":"Pan-cancer alterations of the MYC oncogene and its proximal network across the Cancer Genome Atlas","volume":"6","author":"Schaub","year":"2018","journal-title":"Cell Systems"},{"key":"10.1016\/S0021-9258(17)49933-9_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/S0021-9258(17)49933-9_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrm1703","article-title":"Transcriptional regulation and transformation by Myc proteins","volume":"6","author":"Adhikary","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.semcancer.2006.07.012","article-title":"Conditional transgenic models define how MYC initiates and maintains tumorigenesis","volume":"16","author":"Arvanitis","year":"2006","journal-title":"Semin. Cancer Biol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncb1110","article-title":"A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells","volume":"6","author":"Yeh","year":"2004","journal-title":"Nat. Cell Biol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct. Target. Ther"},{"key":"10.1016\/S0021-9258(17)49933-9_bib9","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/sj.onc.1202199","article-title":"Design and properties of a Myc derivative that efficiently homodimerizes","volume":"17","author":"Soucek","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/S0021-9258(17)49933-9_bib10","first-page":"3507","article-title":"Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis","volume":"62","author":"Soucek","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.cdd.4401443","article-title":"Omomyc expression in skin prevents Myc-induced papillomatosis","volume":"11","author":"Soucek","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/S0021-9258(17)49933-9_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1101\/gad.205542.112","article-title":"Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice","volume":"27","author":"Soucek","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/S0021-9258(17)49933-9_bib13","doi-asserted-by":"crossref","first-page":"e22284","DOI":"10.1371\/journal.pone.0022284","article-title":"The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy","volume":"6","author":"Savino","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/S0021-9258(17)49933-9_bib14","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/onc.2016.354","article-title":"OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors","volume":"36","author":"Jung","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/S0021-9258(17)49933-9_bib15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-13-2281","article-title":"BET bromodomain inhibition of MYC-amplified medulloblastoma","volume":"20","author":"Bandopadhayay","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3892\/or.2015.4410","article-title":"JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms","volume":"35","author":"Choi","year":"2016","journal-title":"Oncol. Rep"},{"key":"10.1016\/S0021-9258(17)49933-9_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/S0021-9258(17)49933-9_bib18","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Ott","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0021-9258(17)49933-9_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-15-0724","article-title":"Dual targeting of bromodomain and extraterminal domain proteins, and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells","volume":"15","author":"T\u00f6gel","year":"2016","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/S0021-9258(17)49933-9_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.7150\/thno.13178","article-title":"BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1","volume":"6","author":"Zhang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/S0021-9258(17)49933-9_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fcell.2017.00010","article-title":"Strategies to inhibit Myc and their clinical applicability","volume":"5","author":"Whitfield","year":"2017","journal-title":"Front. Cell Dev. Biol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40259-019-00370-5","article-title":"Mission possible: advances in MYC therapeutic targeting in cancer","volume":"33","author":"Allen-Petersen","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/S0021-9258(17)49933-9_bib23","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/sj.onc.1209038","article-title":"Involvement of PP2A in viral and cellular transformation","volume":"24","author":"Arroyo","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/S0021-9258(17)49933-9_bib24","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1158\/0008-5472.CAN-05-1103","article-title":"Cancer-associated PP2A A\u03b1 subunits induce functional haploinsufficiency and tumorigenicity","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4161\/cam.1.3.4986","article-title":"The role of PP2A A subunits in tumor suppression","volume":"1","author":"Sablina","year":"2007","journal-title":"Cell Adhesion Migration"},{"key":"10.1016\/S0021-9258(17)49933-9_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Janssens","year":"2001","journal-title":"Biochem. J"},{"key":"10.1016\/S0021-9258(17)49933-9_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gde.2004.12.004","article-title":"PP2A: the expected tumor suppressor","volume":"15","author":"Janssens","year":"2005","journal-title":"Curr. Opin. Genet. Dev"},{"key":"10.1016\/S0021-9258(17)49933-9_bib28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/onc.2017.350","article-title":"Loss of protein phosphatase 2A regulatory subunit B56\u03b4 promotes spontaneous tumorigenesis in vivo","volume":"37","author":"Lambrecht","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/S0021-9258(17)49933-9_bib29","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1158\/0008-5472.CAN-16-2911","article-title":"PP2A inactivation mediated by PPP2R4 haploinsufficiency promotes cancer development","volume":"77","author":"Sents","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10555-008-9128-9","article-title":"A tumor suppressor role for PP2A-B56\u03b1 through negative regulation of c-Myc and other key oncoproteins","volume":"27","author":"Arnold","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/S0021-9258(17)49933-9_bib31","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/MCB.26.7.2832-2844.2006","article-title":"Protein phosphatase 2A regulatory subunit B56\u03b1 associates with c-myc and negatively regulates c-myc accumulation","volume":"26","author":"Arnold","year":"2006","journal-title":"Mol. Cell Biol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib32","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/cc.3.9.1145","article-title":"The life cycle of c-Myc: from synthesis to degradation","volume":"3","author":"Sears","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/S0021-9258(17)49933-9_bib33","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1074\/jbc.M611437200","article-title":"A conserved pathway that controls c-Myc protein stability through opposing phosphorylation events occurs in yeast","volume":"282","author":"Escamilla-Powers","year":"2007","journal-title":"J. Biol. Chem"},{"key":"10.1016\/S0021-9258(17)49933-9_bib34","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1073\/pnas.1317630111","article-title":"Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer","volume":"111","author":"Janghorban","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/S0021-9258(17)49933-9_bib35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1541-7786.MCR-13-0542","article-title":"Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer","volume":"12","author":"Farrell","year":"2014","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib36","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Agarwal","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2016.00078","article-title":"Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia","volume":"6","author":"Arriazu","year":"2016","journal-title":"Front. Oncol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib38","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1038\/srep15182","article-title":"Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET\u2013PP2A signaling axis","volume":"5","author":"Hu","year":"2015","journal-title":"Sci. Rep"},{"key":"10.1016\/S0021-9258(17)49933-9_bib39","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1078-0432.CCR-14-0166","article-title":"SETting OP449 into the PP2A-activating drug family","volume":"20","author":"Neviani","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biocel.2017.10.008","article-title":"Therapeutic targeting of PP2A","volume":"96","author":"O'Connor","year":"2018","journal-title":"Int. J. Biochem. Cell Biol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2014.141","article-title":"Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia: SET binding drugs have antagonistic activity","volume":"28","author":"Pippa","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/S0021-9258(17)49933-9_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fonc.2015.00016","article-title":"Therapeutic re-activation of protein phosphatase 2A in acute myeloid leukemia","volume":"5","author":"Ramaswamy","year":"2015","journal-title":"Front. Oncol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib43","doi-asserted-by":"crossref","first-page":"84214","DOI":"10.18632\/oncotarget.12394","article-title":"Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia","volume":"7","author":"Richard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/S0021-9258(17)49933-9_bib44","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/febs.13573","article-title":"All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase","volume":"283","author":"Sangodkar","year":"2016","journal-title":"FEBS J"},{"key":"10.1016\/S0021-9258(17)49933-9_bib45","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1016\/j.bmc.2015.07.007","article-title":"Reengineered tricyclic anti-cancer agents","volume":"23","author":"Kastrinsky","year":"2015","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/S0021-9258(17)49933-9_bib46","doi-asserted-by":"crossref","first-page":"eaaq1093","DOI":"10.1126\/scitranslmed.aaq1093","article-title":"PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells","volume":"10","author":"Kauko","year":"2018","journal-title":"Sci. Transla. Med"},{"key":"10.1016\/S0021-9258(17)49933-9_bib47","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-17-0123","article-title":"Small-molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer","volume":"78","author":"McClinch","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib48","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI89548","article-title":"Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth","volume":"127","author":"Sangodkar","year":"2017","journal-title":"J. Clin. Invest"},{"key":"10.1016\/S0021-9258(17)49933-9_bib49","doi-asserted-by":"crossref","first-page":"125693","DOI":"10.1172\/jci.insight.125693","article-title":"Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma","volume":"4","author":"Tohm\u00e9","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/S0021-9258(17)49933-9_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/0008-5472.CAN-18-0717","article-title":"Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma","volume":"79","author":"Allen-Petersen","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib51","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/S0021-9258(17)49933-9_bib52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/35074129","article-title":"Somatic activation of the K-ras oncogene causes early onset lung cancer in mice","volume":"410","author":"Johnson","year":"2001","journal-title":"Nature"},{"key":"10.1016\/S0021-9258(17)49933-9_bib53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/304596a0","article-title":"Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes","volume":"304","author":"Land","year":"1983","journal-title":"Nature"},{"key":"10.1016\/S0021-9258(17)49933-9_bib54","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41467-017-01967-6","article-title":"MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance","volume":"8","author":"Farrell","year":"2017","journal-title":"Nat. Commun"},{"key":"10.1016\/S0021-9258(17)49933-9_bib55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature13473","article-title":"Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles","volume":"511","author":"Walz","year":"2014","journal-title":"Nature"},{"key":"10.1016\/S0021-9258(17)49933-9_bib56","first-page":"105","article-title":"The biology of lung cancer","volume":"20","author":"Richardson","year":"1993","journal-title":"Semin. Oncol"},{"key":"10.1016\/S0021-9258(17)49933-9_bib57","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1073\/pnas.0914203107","article-title":"MYC regulation of a \u201cpoor-prognosis\u201d metastatic cancer cell state","volume":"107","author":"Wolfer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/S0021-9258(17)49933-9_bib58","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/bjc.2014.218","article-title":"Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas","volume":"110","author":"Seo","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0021-9258(17)49933-9_bib59","first-page":"4193","article-title":"Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc","volume":"30","author":"Fukazawa","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(00)80308-1","article-title":"Ras enhances Myc protein stability","volume":"3","author":"Sears","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/S0021-9258(17)49933-9_bib61","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1101\/gad.836800","article-title":"Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability","volume":"14","author":"Sears","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/S0021-9258(17)49933-9_bib62","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.3390\/biom7030053","article-title":"MYC-driven pathways in breast cancer subtypes","volume":"7","author":"Fallah","year":"2017","journal-title":"Biomolecules"},{"key":"10.1016\/S0021-9258(17)49933-9_bib63","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1158\/0008-5472.CAN-16-3452","article-title":"MYC inhibition depletes cancer stem-like cells in triple-negative breast cancer","volume":"77","author":"Yang","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/S0021-9258(17)49933-9_bib64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41388-018-0421-y","article-title":"Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/S0021-9258(17)49933-9_bib65","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1084\/jem.20111512","article-title":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","volume":"209","author":"Horiuchi","year":"2012","journal-title":"J. Exp. Med"},{"key":"10.1016\/S0021-9258(17)49933-9_bib66","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1038\/onc.2017.275","article-title":"Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth","volume":"36","author":"Lustig","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/S0021-9258(17)49933-9_bib67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10549-019-05166-3","article-title":"Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer","volume":"175","author":"Lee","year":"2019","journal-title":"Breast Cancer Res. Treat"},{"key":"10.1016\/S0021-9258(17)49933-9_bib68","doi-asserted-by":"crossref","first-page":"80804","DOI":"10.18632\/oncotarget.20534","article-title":"Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems","volume":"8","author":"Nagaria","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/S0021-9258(17)49933-9_bib69","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/S0021-9258(17)49933-9_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ebiom.2017.04.006","article-title":"c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks","volume":"18","author":"Barfeld","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/S0021-9258(17)49933-9_bib71","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1080\/15384101.2015.1093713","article-title":"Deubiquitinating c-Myc: USP36 steps up in the nucleolus","volume":"14","author":"Sun","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/S0021-9258(17)49933-9_bib72","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1101\/gad.1067003","article-title":"Genomic targets of the human c-Myc protein","volume":"17","author":"Fernandez","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/S0021-9258(17)49933-9_bib73","doi-asserted-by":"crossref","first-page":"8164","DOI":"10.1073\/pnas.1332764100","article-title":"A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells","volume":"100","author":"Li","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/S0021-9258(17)49933-9_bib74","doi-asserted-by":"crossref","first-page":"93998","DOI":"10.18632\/oncotarget.21501","article-title":"MYC overexpression with its prognostic and clinicopathological significance in breast cancer","volume":"8","author":"Qu","year":"2017","journal-title":"Oncotarget"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925817499339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925817499339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:19:33Z","timestamp":1758169173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925817499339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":74,"aliases":["10.1074\/jbc.ra119.011443"],"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0021925817499339"],"URL":"https:\/\/doi.org\/10.1016\/s0021-9258(17)49933-9","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0021-9258(17)49933-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}